Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients

Fig. 4

RFS outcomes in the tumor>5 cm and tumor ≤5 cm groups by Fib status (patients with potential follow-up of more than 3 years, n = 826). Notes: a In the tumor size>5 cm group, patients with low Fib levels exhibited better 3-year RFS compared with patients with high Fib levels (77.9% vs 53.8%, log-rank, P = 0.0042). b In the tumor size ≤5 cm group, no significant differences were showed in RFS graphs (log-rank, P = 0.2345). Abbreviations: RFS, recurrence-free survival; Fib, fibrinogen

Back to article page